HMGB1 and cardiovascular disorder: Given its demonstrated safety in China as a medicine for patients with cardiovascular disorders, and its capacity to inhibit HMGB1 release after LPS stimulation, TSN-SS may be a promising therapeutic agent for inhibiting HMGB1 release in clinical settings [27].